Literature DB >> 8955662

Treatment of cancer with radiation and drugs.

I F Tannock1.   

Abstract

PURPOSE: To review the current status and future prospects of combined treatment of cancer with radiation and drugs.
DESIGN: A review of (1) mechanisms whereby combined use of radiation and drugs might lead to improved therapeutic benefit for the treatment of cancer; (2) problems related to the design and analysis of clinical trials that evaluate combined modality treatment; and (3) clinical results of larger randomized trials that have compared combined versus single modality treatment for various types of cancer.
RESULTS: Improvement in the therapeutic index depends on exploitation of the biologic properties that differ between tumors and normal tissues; such properties may include mechanisms of resistance to radiation and drugs, tissue microenvironment, and cell proliferation or repopulation during radiotherapy. To detect or rule out the small but clinically important differences in outcome that might occur will require the performance of large, randomized, controlled trials or patient-based meta-analyses; single-arm studies, small randomized trials, and subgroup analyses of larger trials can generate hypotheses. Clinical gains from combined treatment have been demonstrated in a few sites, with disappointing results in others. In general, more promising results have accrued from concurrent treatment, despite greater toxicity, than from sequential use of drugs and radiation.
CONCLUSION: Clinical gains from combined treatment with radiation and drugs have been small. New, mechanistically based approaches to combined treatment are required.

Entities:  

Mesh:

Year:  1996        PMID: 8955662     DOI: 10.1200/JCO.1996.14.12.3156

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  14 in total

1.  Changes in vascularization of human breast cancer xenografts responding to antiestrogen therapy.

Authors:  C A Kristensen; L M Hamberg; G J Hunter; S Roberge; D Kierstead; G L Wolf; R K Jain
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

2.  Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy.

Authors:  Kenji Ishido; Katsuhiko Higuchi; Satoshi Tanabe; Mizutomo Azuma; Tohru Sasaki; Chikatoshi Katada; Shouko Komori; Kazushige Hayakawa; Kei Hosoda; Keishi Yamashita; Natsuya Katada; Wasaburo Koizumi
Journal:  Jpn J Radiol       Date:  2015-11-17       Impact factor: 2.374

3.  In vitro 3-dimensional tumor model for radiosensitivity of HPV positive OSCC cell lines.

Authors:  Mei Zhang; Barbara Rose; C Soon Lee; Angela M Hong
Journal:  Cancer Biol Ther       Date:  2015-06-05       Impact factor: 4.742

4.  Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer.

Authors:  Masashi Kobayashi; Kaoru Matsui; Tomonori Hirashima; Takashi Nitta; Shinji Sasada; Takuhito Tada; Kazuo Minakuchi; Mitsugi Furukawa; Yoshitaka Ogata; Ichiro Kawase
Journal:  Int J Clin Oncol       Date:  2006-08       Impact factor: 3.402

5.  Management of Stage I Squamous Cell Carcinoma of the Anal Canal.

Authors:  Christy Y Chai; Hop S Tran Cao; Samir Awad; Nader N Massarweh
Journal:  JAMA Surg       Date:  2018-03-01       Impact factor: 14.766

Review 6.  New approaches in the use of radiation therapy in the treatment of infiltrative transitional-cell cancer of the bladder.

Authors:  P Warde; M K Gospodarowicz
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 7.  Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy.

Authors:  Matthew J Matasar; Vijaya Sundararajan; Victor R Grann; Alfred I Neugut
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  Molecular targets for tumor radiosensitization.

Authors:  Philip J Tofilon; Kevin Camphausen
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

9.  Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).

Authors:  M van Heijl; J J B van Lanschot; L B Koppert; M I van Berge Henegouwen; K Muller; E W Steyerberg; H van Dekken; B P L Wijnhoven; H W Tilanus; D J Richel; O R C Busch; J F Bartelsman; C C E Koning; G J Offerhaus; A van der Gaast
Journal:  BMC Surg       Date:  2008-11-26       Impact factor: 2.102

10.  Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model.

Authors:  K J Harrington; K N Syrigos; P S Uster; A Zetter; C R Lewanski; W J Gullick; R G Vile; J S W Stewart
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.